AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees Philadelphia, PA

Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers,

and Change of Members of the Committees

PA, July 14, 2022 - AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we")

(ANPC), a biotechnology company with operations in the United States and China focused on early

cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members

(the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change

of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a

general meeting in accordance with British Virgin Islands law, which allows Member's resolutions to be approved by written resolutions

signed by a majority of the votes of all Members entitled to vote on the resolution at a general meeting.

proposals authorized (1) the removal of Aidong Chen and Sheng Liu as Directors, the removal of Aidong Chen as (a) Co-Chairman of the

Board of Directors of the Company and (b) Co-Chief Executive

Officer of the Company, effective immediately without compensation for loss of office; (2) the re-designation of Chris Chang Yu as (a)

Chief Executive Officer of the Company and (b) Chairman of the Board, approved with immediate effect; (3) the removal of Sheng Liu as

the chairman of the Nomination Committee of the Board and as a member of the Compensation Committee of the Board, effective immediately,

and (4) the appointment of Chris Chang Yu as the chairman of the Nomination Committee of the Board and as a member of the Compensation

Committee of the Board.

Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2022. With two

certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs

a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics

tests. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multi-cancer screening and detection test sample

volume (accumulative to January 2021). AnPac Bio's CDA technology platform has been shown in retrospective validation studies to

be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

more information, please visit: https://www.Anpacbio.com.

investor and media inquiries, please contact:

Case, Marketing and Investor Relations

+1-267-810-6776 (US)

Investor Relations LLC

Tina Xiao, President

Phone: +1-917-609-0333 (US)

Email: tina.xiao@ascent-ir.com

announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of

the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the

Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance.

The Company has attempted to identify forward-looking statements by terminologies including "believes,"

"estimates," "anticipates," "expects," "plans," "projects,"

"intends," "potential," "target," "aim," "predict,"

"outlook," "seek," "goal" "objective," "assume,"

"contemplate," "continue," "positioned," "forecast," "likely,"

"may," "could," "might," "will," "should," "approximately"

or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements

are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic,

competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and

many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other

factors that may cause the Company's actual results to be materially different from those expressed or implied by any

forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to

comply with Nasdaq Listing Rules, the implementation of our business model and growth strategies; trends and competition in the

cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and

detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections

for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain

and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or

accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our

ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions

in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and

customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial

markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and

travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus.

Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the

Company's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because

of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In

addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company

undertakes no obligation to revise or update publicly any forward-looking statements for any reason.